Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2012

View Archived Issues

Allergan presents new S1P1 receptor ligands

Randomized trial shows benefit of armodafinil in patients with traumatic brain injury

Phase I/Ib trial evaluates AUY-922 alone and with bortezomib

Encouraging phase II results presented on PD-0332991

New LDL-PLA2 inhibitors developed by GlaxoSmithKline

Italian researchers disclose novel EP4 receptor antagonists

Roche divulges novel Mdm2/p53 interaction inhibitors

Chinese group reports new antivirals

U.S. university patents new polypeptides

Epizyme synthesizes novel DOT1-like protein inhibitors

Amitiza approved in Japan

Debio-0932 shows promising activity in patients with advanced solid tumors

Sirnaomics plans siRNA-based therapeutic study in China

Ultragenyx begins dosing in new UX-001 study

Pfizer grants ChemRar rights to DPP IV inhibitor

Prosonix and Imperial College London to collaborate on engineered combination respiratory medicines

FDA accepts Adasuve NDA resubmission

Optimer obtains approval in Canada for CDI treatment

Health Canada approves Jakavi for treatment of patients with myelofibrosis

New models of kidney cancer developed in U.S.

MK-6096 effective in multinational trial

Companies file application in Japan for oral imaging agent for malignant glioma

FDA approves first test for quantifying CMV DNA in human plasma

Amgen completes acquisition

New public-private partnership aims to develop pediatric formulation of schistosomiasis treatment

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...